Corazzelli, Gaetano <br/><br/>
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.  [electronic resource] 

 -  British journal of haematology  Sep 2011 
 - 579-89 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2011.08786.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Comorbidity<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Heart Diseases--drug therapy<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--complications<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--administration & dosage<br/>Prednisone--administration & dosage<br/>Prognosis<br/>Risk<br/>Rituximab<br/>Survival Analysis<br/>Treatment Outcome<br/>Vincristine--administration & dosage